Expanded Access Available for Satraplatin

At the 2007 Prostate Cancer Symposium in Orlando, GPC Biotech announced that, for a limited time, they are making available to U.S. investigators, an “expanded access” program for Satraplatin. Expanded access programs are normally for patients who do not qualify for ongoing clinical trials.

Satraplatin is an orally administered platinum compound currently under investigation for the treatment of patients with advanced hormone-refractory prostate cancer (HRPC) that has failed prior chemotherapy.

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) (SPERA)
NCT00450970 – Currently Recruiting – Location: Various in USA

The Phase III SPERA trial is designed to:

1. provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following one prior cytotoxic chemotherapy regimen for metastatic disease and
    
2. evaluate the safety of oral satraplatin in this patient population.

Also presented February 23, 2007:

Satraplatin Shown to Significantly Reduce Risk of Disease Progression in Advanced Hormone-Refractory Prostate Cancer Patients

• highly statistically significant results for improvement in progression-free survival

• progression-free survival results consistent irrespective of prior chemotherapy treatment, including taxotere®

• satraplatin was well tolerated with myelosuppression the most commonly observed toxicity

To view the full press release

To learn more about the the expanded access program, ask your physician: to contact GPC Biotech at: 1-800-349-8086 or to access www.speratrial.com.

 

Prostate Cancer Research Institute (PCRI)
 

Material provided by PCRI is intended for educational purposes for discussion with your physician and should not be considered as medical advice. Information and opinions expressed on this website are not an endorsement by PCRI for any treatment, product or service.